Does Rallies show Form 4 insider transactions for CRMD?

Yes. Rallies tracks CRMD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CRMD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRMD. It does not provide personalized investment advice.

CRMD (CorMedix Inc.) Stock Analysis - Insider Trades

CorMedix Inc. (CRMD) is a publicly traded Healthcare sector company. As of May 21, 2026, CRMD trades at $7.94 with a market cap of $620.55M and a P/E ratio of 3.42. CRMD moved +1.41% today. Year to date, CRMD is -34.95%; over the trailing twelve months it is -38.14%. Its 52-week range spans $5.60 to $17.43. Analyst consensus is strong buy with an average price target of $14.25. Rallies surfaces CRMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CRMD stock inside the company?

Recent CRMD insider activity includes Dillione Janet sold 10.00K, DUNTON ALAN W sold 20.00K, Todisco Joseph sold 30.00K, Dillione Janet sold 34.00K, and Lefkowitz Steven W sold 40.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CRMD Key Metrics

Key financial metrics for CRMD
Metric	Value
Price	$7.94
Market Cap	$620.55M
P/E Ratio	3.42
EPS	$2.32
Dividend Yield	0.00%
52-Week High	$17.43
52-Week Low	$5.60
Volume	544
Avg Volume	0
Revenue (TTM)	$400.05M
Net Income	$181.01M
Gross Margin	85.83%

Recent CRMD Insider Trades

Dillione Janet sold 10.00K (~$68.80K) on Jan 21, 2026.
DUNTON ALAN W sold 20.00K (~$260.00K) on Dec 30, 2025.
Todisco Joseph sold 30.00K (~$360.00K) on Dec 18, 2025.
Dillione Janet sold 34.00K (~$408.00K) on Dec 9, 2025.
Lefkowitz Steven W sold 40.00K (~$475.20K) on Dec 9, 2025.

Latest CRMD News

Cormedix Hikes FY Revenue to $345M and EBITDA to $135M After Q1 — May 14, 2026
CorMedix Phase III Trial Shows 60.7% Fungal-Free Survival Versus 59.0% Regimen — Apr 27, 2026
CorMedix to Host April 14 Virtual Fireside Chat at Healthcare Conference — Apr 7, 2026
CorMedix Q4 Revenue Hits $128.6M, Achieves $35M Synergies with Melinta Deal — Mar 6, 2026
CorMedix Misses Q4 Estimates, Affirms $300–320M 2026 Guidance and Warns of Price Erosion — Mar 5, 2026

CRMD Analyst Consensus

5 analysts cover CRMD: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.25.

Common questions about CRMD

Who is trading CRMD stock inside the company?: Recent CRMD insider activity includes Dillione Janet sold 10.00K, DUNTON ALAN W sold 20.00K, Todisco Joseph sold 30.00K, Dillione Janet sold 34.00K, and Lefkowitz Steven W sold 40.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CRMD?: Yes. Rallies tracks CRMD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CRMD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRMD. It does not provide personalized investment advice.